A
Arvinas D
D
ARVN
7.13000
USD
-0.29
(-3.84%)
Market Closed
Volume
36,390
EPS
-3
Div Yield
-
P/E
-2
Market Cap
460,036,142
Title: Arvinas
Sector: Healthcare
Industry: Biotechnology
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases.






